Top

Published in:

01-06-2007

Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis

Author: Kendall B. Wallace

Published in: Cardiovascular Toxicology | Issue 2/2007

Abstract

Adriamycin (doxorubicin) is a potent and broad-spectrum antineoplastic agent, the clinical utility of which is limited by the development of a cumulative and irreversible cardiomyopathy. Although the drug affects numerous structures in different cell types, the mitochondrion appears to a principal subcellular target for the development of cardiomyopathy. This review describes evidence demonstrating that adriamycin redox cycles on complex I of the mitochondrial electron transport chain to liberate highly reactive free radical species of molecular oxygen. The primary effect of adriamycin on mitochondrial performance is the interference with oxidative phosphorylation and inhibition of ATP synthesis. Free radicals liberated from adriamycin redox cycling are thought to be responsible for many of the secondary effects of adriamycin, including lipid peroxidation, the oxidation of both proteins and DNA, and the depletion of glutathione and pyridine nucleotide reducing equivalents in the cell. It is this altered redox status that is believed to cause assorted changes in intracellular regulation, including the induction of the mitochondrial permeability transition and complete loss of mitochondrial integrity and function. Associated with this is the interference with mitochondrial-mediated cell calcium signaling, which is implicated as essential to the capacity of mitochondria to participate in bioenergetic regulation in response to external signals reflecting changes in metabolic demand. If taken to an extreme, this loss of mitochondrial plasticity may manifest in the liberation of signals mediating either oncotic or necrotic cell death, further perpetuating the cardiac failure associated with adriamycin-induced mitochondrial cardiomyopathy.

Lefrak, E. A., Pitha, J., Rosenheim, S., & Gottlieb J. A. (1973). A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer, 32(2), 302–314.PubMedCrossRef

Gewirtz, D. A. (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochemical Pharmacology, 57(7), 727–741.PubMedCrossRef

Ferrans, V. J., Clark, J. R., Zhang, J., Yu, Z. X., & Herman, E. H. (1997). Pathogenesis and prevention of doxorubicin cardiomyopathy. Tsitologiia, 39(10), 928–937.PubMed

Olson, R. D., & Mushlin, P. S. (1990). Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses [see comments]. FASEB Journal, 4(13), 3076–3086.PubMed

Singal, P. K., & Iliskovic N. (1998). Doxorubicin-induced cardiomyopathy [see comments]. New England Journal of Medicine, 339(13), 900–905.PubMedCrossRef

Lou, H., Kaur, K., Sharma, A. K., & Singal, P. K. (2006). Adriamycin-induced oxidative stress, activation of MAP kinases and apoptosis in isolated cardiomyocytes. Pathophysiology, 13, 103–109.PubMedCrossRef

Tokarska-Schlattner, M., Wallimann, T., & Schlattner, U. (2006). Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin. Comptes Rendus Biology, 329, 657–668.CrossRef

Mailer, K., & Petering, D. H. (1976). Inhibition of oxidative phosphorylation in tumor cells and mitochondria by daunomycin and adriamycin. Biochemical Pharmacology, 25(18), 2085–2089.PubMedCrossRef

Herman, E. H., el-Hage, A. N., Creighton, A. M., Witiak, D. T., & Ferrans, V. J. (1985). Comparison of the protective effect of ICRF-187 and structurally related analogues against acute daunorubicin toxicity in Syrian golden hamsters. Research Communications in Chemical Pathology and Pharmacology, 48(1), 39–55.PubMed

10.

Lebrecht, D., Kokkori, A., Ketelsen, U. P., Setzer, B., & Walker, U. A. (2005). Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. Journal of Pathology, 207, 436–444.PubMedCrossRef

11.

Wallace, K. B. (2003). Doxorubicin-induced cardiac mitochondrionopathy. Pharmacology & Toxicology, 93, 105–115.CrossRef

12.

Berthiaume, J. M., & Wallace K. B. (2007). Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biology and Toxicology, 23, 15–25.PubMedCrossRef

13.

Brown, H. R., Ni, H., Benavides, G., Yoon, L., Hyder, K., Giridhar, J., Gardner, G., Tyler, R. D., & Morgan, K. T. (2002). Correlation of simultaneous differential gene expression in the blood and heart with known mechanisms of adriamycin-induced cardiomyopathy in the rat. Toxicologic Pathology, 30, 452–469.PubMedCrossRef

14.

Marcillat, O., Zhang, Y., & Davies, K. J. (1989). Oxidative and non-oxidative mechanisms in the inactivation of cardiac mitochondrial electron transport chain components by doxorubicin. Biochemical Journal, 259, 181–189.PubMed

15.

Neri, B., Cini-Neri, G., & D’Alterio, M. (1984). Effect of anthracyclines and mitoxantrone on oxygen uptake and ATP intracellular concentration in rat heart slices. Biochemical and Biophysical Research Communications, 125, 954–960.PubMedCrossRef

16.

Aversano, R. C., & Boor, P. J. (1983). Histochemical alterations of acute and chronic doxorubicin cardiotoxicity. Journal of Molecular and Cellular Cardiology, 15(8), 543–553.PubMedCrossRef

17.

Davies, K. J., & Doroshow, J. H. (1986). Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. Journal of Biological Chemistry, 261(7), 3060–3067.PubMed

18.

Doroshow, J. H., & Davies K. J. (1986). Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. Journal of Biological Chemistry, 261(7), 3068–3074.PubMed

19.

Solem, L. E., Henry, T. R., & Wallace, K. B. (1994). Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration. Toxicology and Applied Pharmacology, 129(2), 214–222.PubMedCrossRef

20.

Santos, D. L., Moreno, A. J. M. , Leino, R. L., Froberg, M. K., & Wallace, K. B. (2002). Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicology and Applied Pharmacology, 184, 218–227.CrossRef

21.

Mimnaugh, E. G., Trush, M. A., Bhatnagar, M., & Gram T. E. (1985). Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin. Biochemical Pharmacology, 34(6), 847–856.PubMedCrossRef

22.

Boucek, R. J. Jr., Olson, R. D., Brenner, D. E., Ogunbunmi, E. M., Inui, M., & Fleischer, S. (1987). The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. Journal of Biological Chemistry, 262(33), 15851–15856.PubMed

23.

Goormaghtigh, E., Huart, P., Praet, M., Brasseur, R., & Ruysschaert, J. M. (1990). Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity. Biophysical Chemistry, 35(2–3), 247–257.PubMedCrossRef

24.

Gosalvez, M., Blanco, M., Hunter, J., Miko, M., & Chance, B. (1974). Effects of anticancer agents on the respiration of isolated mitochondria and tumor cells. European Journal of Cancer, 10(9), 567–574.PubMed

25.

Singal, P. K., Deally, C. M., & Weinberg, L. E. (1987). Subcellular effects of adriamycin in the heart: a concise review. Journal of Molecular and Cellular Cardiology, 19(8), 817–828.PubMedCrossRef

26.

Ferrero, M. E., Ferrero, E., Gaja, G., & Bernelli-Zazzera, A. (1976). Adriamycin: Energy metabolism and mitochondrial oxidations in the heart of treated rabbits. Biochemical Pharmacology, 25(2), 125–130.PubMedCrossRef

27.

Hoek, J. B., Farber, J. L., Thomas, A. P., & Wang, X. (1995). Calcium ion-dependent signalling and mitochondrial dysfunction: Mitochondrial calcium uptake during hormonal stimulation in intact liver cells and its implication for the mitochondrial permeability transition. Biochimica et Biophysica Acta, 1271(1), 93–102.PubMed

28.

Miyata, H., Silverman, H. S., Sollott, S. J., Lakatta, E. G., Stern, M. D., & Hansford, R. G. (1991). Measurement of mitochondrial free Ca²⁺ concentration in living single rat cardiac myocytes. American Journal of Physiology, 261(4 Pt 2), H1123–H1134.PubMed

29.

Sparagna, G. C., Gunter, K. K., Sheu, S. S., & Gunter, T. E. (1995). Mitochondrial calcium uptake from physiological-type pulses of calcium. A description of the rapid uptake mode. Journal of Biological Chemistry, 270(46), 27510–27515.PubMedCrossRef

30.

Rudge, M. F., & Duncan, C. J. (1984). Comparative studies on the role of calcium in triggering subcellular damage in cardiac muscle. Comparative Biochemistry and Physiology A, 77(3), 459–468.CrossRef

31.

Li, Q., Hohl, C. M., Altschuld, R. A., & Stokes, B. T. (1989). Energy depletion-repletion and calcium transients in single cardiomyocytes. American Journal of Physiology, 257(3 Pt 1), C427–C434.PubMed

32.

Solem, L. E., Heller, L. J., & Wallace, K. B. (1996). Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by doxorubicin. Journal of Molecular and Cellular Cardiology, 28(5), 1023–1032.PubMedCrossRef

33.

Solem, L. E., & Wallace, K. B. (1993). Selective activation of the sodium-independent, cyclosporine A-sensitive calcium pore of cardiac mitochondria by doxorubicin. Toxicology and Applied Pharmacology, 121(1), 50–57.PubMedCrossRef

34.

Bachmann, E., & Zbinden, G. (1979). Effect of doxorubicin and rubidazone on respiratory function and Ca²⁺ transport in rat heart mitochondria. Toxicology Letters, 3, 29–34.CrossRef

35.

Chacon, E., & Acosta, D. (1991). Mitochondrial regulation of superoxide by Ca²⁺: An alternate mechanism for the cardiotoxicity of doxorubicin. Toxicology and Applied Pharmacology, 107(1), 117–128.PubMedCrossRef

36.

Sokolove, P. M., & Shinaberry, R. G. (1988). Na⁺-independent release of Ca²⁺ from rat heart mitochondria. Induction by adriamycin aglycone. Biochemical Pharmacology, 37(5), 803–812.PubMedCrossRef

37.

Sokolove, P. M. (1990). Inhibition by cyclosporine A and butylated hydroxytoluene of the inner mitochondrial membrane permeability transition induced by adriamycin aglycones. Biochemical Pharmacology, 40(12), 2733–2736.PubMedCrossRef

38.

Singal, P. K., Forbes, M. S., & Sperelakis, N. (1984). Occurrence of intramitochondrial Ca²⁺ granules in a hypertrophied heart exposed to adriamycin. Canadian Journal of Physiology and Pharmacology, 62, 1239–1244.PubMed

39.

Gunter, K. K., & Gunter, T. E. (1994). Transport of calcium by mitochondria. Journal Of Bioenergetics and Biomembranes, 26(5), 471–485.PubMedCrossRef

40.

Gunter, T. E., & Pfeiffer, D. R. (1990). Mechanisms by which mitochondria transport calcium. American Journal of Physiology, 258(5 Pt 1), C755–C786.PubMed

41.

Denton, R. M., & McCormack, J. G. (1990). Ca²⁺ as a second messenger within mitochondria of the heart and other tissues. Annual Review of Physiology, 52, 451–466.PubMedCrossRef

42.

Bernardi, P., Broekemeier, K. M., & Pfeiffer, D. R. (1994). Recent progress on regulation of the mitochondrial permeability transition pore; a sensitive-sensitive pore in the inner mitochondrial membrane. Journal Of Bioenergetics and Biomembranes, 26(5), 509–517.PubMedCrossRef

43.

Al-Nasser, I. A. (1998). In vivo prevention of adriamycin cardiotoxicity by cyclosporine A or FK506. Toxicology, 131, 175–181.PubMedCrossRef

44.

Zhou, S., Starkov, A., & Wallace, K. B. (2001). Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Research, 61, 771–777.PubMed

45.

Bernardi, P. (1999). Mitochondrial transport of cations: Channels, exchangers, and permeability transition. Physiological Reviews, 79(4), 1127–1155.PubMed

46.

Richter, C., & Schlegel, J. (1993). Mitochondrial calcium release induced by prooxidants. Toxicology Letters, 67(1–3), 119–127.PubMedCrossRef

47.

Wallace, K. B., Eells, J. T., Madeira, V. M., Cortopassi, G., & Jones, D. P. (1997). Mitochondria-mediated cell injury. Symposium overview. Fundamental and Applied Toxicology, 38(1), 23–37.PubMedCrossRef

48.

Imberti, R., Nieminen, A. L., Herman, B., & Lemasters, J. J. (1993). Mitochondrial and glycolytic dysfunction in lethal injury to hepatocytes by t-butylhydroperoxide: Protection by fructose, cyclosporine A and trifluoperazine. Journal of Pharmacology and Experimental Therapeutics, 265(1), 392–400.PubMed

49.

Groskreutz, J. L., Bronk, S. F., & Gores, G. J. (1992). Ruthenium red delays the onset of cell death during oxidative stress of rat hepatocytes. Gastroenterology, 102(3), 1030–1038.PubMed

50.

Pastorino, J. G., Snyder, J. W., Serroni, A., Hoek, J. B., & Farber, J. L. (1993). Cyclosporine and carnitine prevent the anoxic death of cultured hepatocytes by inhibiting the mitochondrial permeability transition. Journal of Biological Chemistry, 268(19), 13791–13798.PubMed

51.

Henry, T. R., & Wallace, K. B. (1996). Differential mechanisms of cell killing by redox cycling and arylating quinones. Archives of Toxicology, 70(8), 482–489.PubMedCrossRef

52.

Petronilli, V., Cola, C., Massari, S., Colonna, R., & Bernardi, P. (1993). Physiological effectors modify voltage sensing by the cyclosporine A- sensitive permeability transition pore of mitochondria. Journal of Biological Chemistry, 268(29), 21939–21945.PubMed

53.

Petronilli, V., Cola, C., & Bernardi, P. (1993). Modulation of the mitochondrial cyclosporine A-sensitive permeability transition pore. II. The minimal requirements for pore induction underscore a key role for transmembrane electrical potential, matrix pH, and matrix Ca2+. Journal of Biological Chemistry, 268(2), 1011–1016.PubMed

54.

Petronilli, V., Nicolli, A., Costantini, P., Colonna, R., & Bernardi, P. (1994). Regulation of the permeability transition pore, a voltage-dependent mitochondrial channel inhibited by cyclosporine A. Biochimica et Biophysica Acta, 1187(2), 255–259.PubMedCrossRef

55.

Petronilli, V., Costantini, P., Scorrano, L., Colonna, R., Passamonti, S., & Bernardi, P. (1994). The voltage sensor of the mitochondrial permeability transition pore is tuned by the oxidation-reduction state of vicinal thiols. Increase of the gating potential by oxidants and its reversal by reducing agents. Journal of Biological Chemistry, 269(24), 16638–16642.PubMed

56.

Fagian, M. M., Pereira-da-Silva, L., Martins, I. S., & Vercesi, A. E. (1990). Membrane protein thiol cross-linking associated with the permeabilization of the inner mitochondrial membrane by Ca²⁺ plus prooxidants. Journal of Biological Chemistry, 265(32), 19955–19960.PubMed

57.

Meredith, M. J., & Reed, D. J. (1983). Depletion in vitro of mitochondrial glutathione in rat hepatocytes and enhancement of lipid peroxidation by adriamycin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochemical Pharmacology, 32(8), 1383–1388.PubMedCrossRef

58.

Oliveira, P. J., & Wallace, K. B. (2006). Depletion of adenine nucleotide translocator protein in heart mitochodria from doxorubicin-treated rats—Relevance for mitochondrial dysfunction. Toxicology, 220, 160–168.PubMedCrossRef

59.

Halestrap, A. P., Woodfield, K. Y., & Connern, C. P. (1997). Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. Journal of Biological Chemistry, 272(6), 3346–3354.PubMedCrossRef

60.

Halestrap, A. P., Kerr, P. M., Javadov, S., & Woodfield, K. Y. (1998). Elucidating the molecular mechanism of the permeability transition pore and its role in reperfusion injury of the heart. Biochimica et Biophysica Acta, 1366(1–2), 79–94.PubMedCrossRef

61.

Oliveira, P. J., Santos, M. S., & Wallace, K. B. (2005). Doxorubicin-induced thiol-dependent alteration of cardiac mitochondrial permeability transition and respiration. Biochemistry (Moscow), 71, 194–199.CrossRef

62.

Serrano, J., Palmeira, C. M., Kuehl, D. W., & Wallace, K. B. (1999). Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. Biochimica et Biophysica Acta, 1411(1), 201–205.PubMedCrossRef

63.

Palmeira, C. M., Serrano, J., Kuehl, D. W., & Wallace, K. B. (1997). Preferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicin. Biochimica et Biophysica Acta, 1321(2), 101–106.PubMedCrossRef

64.

Zhou, S., Palmeira, C. M., & Wallace, K. B. (2001). Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicology Letters, 121, 151–157.PubMedCrossRef

65.

Chacon, E., Ohata, H., Harper, I. S., Trollinger, D. R., Herman, B., & Lemasters, J. J. (1996). Mitochondrial free calcium transients during excitation-contraction coupling in rabbit cardiac myocytes. FEBS Letters, 382(1–2), 31–36.PubMedCrossRef

66.

Herrington, J., Park, Y. B., Babcock, D. F., & Hille, B. (1996). Dominant role of mitochondria in clearance of large Ca²⁺ loads from rat adrenal chromaffin cells. Neuron, 16(1), 219–228.PubMedCrossRef

67.

Isenberg, G., Han, S., Schiefer, A., & Wendt-Gallitelli, M. F. (1993). Changes in mitochondrial calcium concentration during the cardiac contraction cycle. Cardiovascular Research, 27(10), 1800–1809.PubMedCrossRef

68.

Gillis, J. M. (1997). Inhibition of mitochondrial calcium uptake slows down relaxation in mitochondria-rich skeletal muscles. Journal of Muscle Research and Cell Motility, 18(4), 473–483.PubMedCrossRef

69.

Loew, L. M., Carrington, W., Tuft, R. A., & Fay, F. S. (1994). Physiological cytosolic Ca²⁺ transients evoke concurrent mitochondrial depolarizations. Proceedings of the National Academy of Sciences of the United States of America, 91(26), 12579–12583.

70.

Zhou, S., Heller, L. J., & Wallace, K. B. (2001). Interferences with calcium-dependent mitochondrial bioenergetics in cardiac myocytes isolated from doxorubicin-treated rats. Toxicology and Applied Pharmacology, 175, 60–67.PubMedCrossRef

Title: Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis
Author: Kendall B. Wallace
Publication date: 01-06-2007
Publisher: Humana Press Inc
Published in: Cardiovascular Toxicology / Issue 2/2007
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-007-0008-2

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2007

Iron signaling and oxidant damage

Ongoing phase I and II studies of novel anthracyclines

Molecular and cellular mechanisms of anthracycline cardiotoxicity

Anthracycline-induced phospholipase A2 inhibition

The anthracyclines: When good things go bad

Genotyping the risk of anthracycline-induced cardiotoxicity

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page